Viral Vector Upstream Platforms

The VirusExpress™ Lentiviral Production Platform features a suspension adapted cell line, chemically defined medium, and production process with proven performance

Figure 1.The VirusExpress® Production Platform features a suspension adapted cell line, chemically defined medium, and production process with proven performance.

The VirusExpress® Production Platform offers a transfection-based solution to lentivirus (LV) or adeno-associated virus (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and production process with proven performance at up to 50 L scale.

With a platform that can dramatically reduce the time in process development and scale-up, whether performed in your facilities or leveraging our gene therapy CDMO capabilities, you can draw on our experience to speed your gene therapy to patients.



Key Advantages Include

  • GMP banked and fully characterized cell bank manufactured in accordance with 21 CFR 210, 211, 600, 610
  • Proven performance for cell growth, plasmid transfection, and production in large-scale bioreactors at clinically and commercially relevant scale
  • Licenses available for research or clinical/commercial use
  • Reduction of up to 40% in process development and scale-up time

The VirusExpress® Production Platforms Include

VirusExpress® 293T Lentiviral Production Cells or VirusExpress® 293 AAV Production Cells

  • Cells banked and characterized in conformance with FDA cGMP regulations (21 CFR 201, 211, 600, 610)
  • Suspension-adapted cells
  • Cells optimized for transient transfection processes

EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically-defined, animal component-free, cGMP manufactured cell culture medium

Proven Process

  • Upstream production and downstream purification processes developed at clinically relevant scale

VirusExpress® Production Platform Specifications